We retrospectively analyzed the results of263 consecutive Methacholine challenge tests (MCTs) done in our laboratory between July 2000 and June 2003, in symptomatic adult patients with no history of bronchial asthma or chronic lung disease, who presented with chronic nonproductive cough, shortness of breath (subjective dyspnea), or both. All of these patients had normal results of chest physical examination, chest radiographs and screening spirometry measurements (FEV l >80% of predicted). We considered a 20% fall in the forced expiratory volume in the first second (FEVJ as the primary outcome measure (MCT PC 20-FEV1X and a 35% fall in the specific conductance (sGaw) as the primary outcome in patients who cannot perform acceptable spirometry. Out of263 patients, 79pa-tients (30%) were positive for bronchial hyper-responsiveness (BHR), 20 patients (25.3%) of the positive patients had sever BHR, 18 patients (22.8%) had moderate BHR, and 41 patients (51.9%) had mild BHR.
testing is potentially useful as bronchial hyper-responsiveness (BHR) may be the sole evidence of airway dysfunction (3) . The degree of BHR in a symptomatic person can have a prognostic and a potentially therapeutic value 4) .
In this 3-year retrospective study, we reviewed the results of MCT's done in 263 adult patients referred with chronic cough, subjective dyspnea or both to the Adult Allergy and Pulmonary Diseases Section, Hamad Medical Corporation during the period from July 2000 to June 2003, to determine the existence of BHR among those patients.
Material and Methods:
Patients: There were 263 patients seen in the pulmonary outpatient clinic at Hamad Medical Corporation, between July 2000 and June 2003. Hamad Medical Corporation is a public hospital with 1200 beds and is the only hospital in Qatar providing acute medical care for the 650,000 populations. All the patients in the study were adults aged 12-70 years with a mean age of 35.8 years. One hundred and twenty four patients (47%) were males and 139 patients (53%) were non-pregnant females. One hundred and sixty patients (60.8 %) were Qatari, and 103 patients (39.2%) were expatriates ( Table 1) . Duration of symptoms ranged from 6 weeks to 12 months (mean of 3 months), 208 patients (79%) complained of chronic cough, 79 patients (30%) complained of shortness of breath. (24 patients (9%) complained of both chronic cough and shortness of breath). (Table 1) None of the patients had past history of bronchial asthma or cardiopulmonary disease, and all had normal results of chest physical examination, chest radiographs and screening spirometry (FEVj > 80% predicted, FEF 25 75% > 70%). There were no patients taking any drug that may cause cough or bronchospasm, and there was no contraindications for the test. Only 6 patients were smokers, however they were instructed to refrain from smoking for at least 6 hours before the test as it may affect the results of the test. At the time of the test, no patient had suffered an upper respiratory tract infection in the previous 3 weeks. The patients were instructed to refrain from food like coffee, tea, cola drinks, and chocolate, and medications like Beta-agonist inhaler, oral theophyllin, and oral antihistamine) that might interfere with the test results were discontinued prior to the test, according to the ATS guidelines for MCT 1999 (5) .
PFT laboratory: All tests were done in the pulmonary function laboratory at Hamad Medical Corporation, by the same technicians and PFT machines, using V max-22 series Sensor Medics PFT analyzer with V 6200 variable pressure constant volume body plethysmography. Flow volume curves, and time volume curves were generated through standard technique with the patients in sitting position. For all patients the best of three flow volume loops was used for analysis.
Provocative agent: Provocholine, which is methacholine chloride powder for inhalation from Methaphram inc. (Brantford, Ontario, Canada). Provocholine is a para-sympathomimetic (cholinergic) synthetic analogue of acetylcholine. It is a bronchoconstrictor agent, to be administered in solution by inhalation for diagnostic purposes. Each 20 ml vial of Provocholine contains 100 mg of Methacholine chloride powder, which is reconstituted with a diluent. The diluent recommended by the manufacturer is 0.9% sodium chloride containing 0.4% phenol (pH 7.0) (6) .
Methacholine challenge test (MCT):
We used the dilution scheme provided in the Provocholine product information handbook using methacholine concentration of 0.025, 0.25, 2.5,10, and 25 mg/ml (Table: 2). Provocholine solution was prepared and stored in accordance with the manufacturer's instructions^. The nebulizer was used to deliver the Methacholine dose as aerosol that is inhaled slowly through the patient's mouth to the lungs, while the nose was closed via a noseclip. A baseline spirometry was done for all patients before challenge.
The five-breath dosimeter protocol was used according to ATS guidelines for MCT 1999 (5) . The test was performed by giving the patient ascending serial concentrations of Provocholine. At each concentration, five breaths were administered by the nebulizer. At each of the five inhalations of a particular concentration, the patient begins at functional residual capacity and slowly and completely inhales the dose delivered (it takes about 5 seconds) then he/she holds breathing for 5 seconds, and then exhales. Within 5 minutes, FEV1 values were determined. The procedure ends either when the primary outcome measure was reached, i.e. there is a 20% or greater reduction in the FEV1 (PC 20-FEV1), compared with the baseline diluent (phenol-containing saline) value (6) , or if the total cumulative units (the highest concentration, 25 mg/ml) has been administered. In 2 patients who could not perform acceptable spirometry maneuvers, measurement of airway resistance (Raw) that is usually expressed as specific conductance (sGaw) was done using body plethysmography. A 35% or greater fall in sGaw was the primary outcome in these 2 cases (5, 7) . An inhaled nebulized G-agonist was administered at the end of the test (6) .
A graph is drawn plotting the fall in the outcome indicator (FEV1 or sGaw) versus the concentration of provocative agent (Methacholine). The effective concentration that would have resulted in a given change in the outcome indicator was determined by interpolation. This provocative concentration was used to interpret the test.
Interpretation of MCT:
The interpretation of the result of MCT in our laboratory was considered as follows:
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Positive MCT: there are three grades as follows:
Severe BHR: PC 20-FEV1 was 2.5 mg/ml or less (i.e. Concentration E, D, and C), there is severe BHR (Bronchial asthma).
Moderate BHR : PC 20-FEV1 is 10 mg/ml, there is moderate BHR, (Possible asthma)
Mild BHR : PC 20-FEV1 is 25 mg/ml there is mild BHR (It could be due to a cause other than asthma such as post-viral upper respiratory tract infection) ( Table 3 ). Data are expressed as mean and standard deviation (SD) unless otherwise stated. Chi-square analysis was performed to test for differences in proportions of categorical variables between two or more groups. In 2 x 2 tables, the Fisher exact test (two-tailed) was used instead of Chi-Square, in particular, when sample size was small. The level p<0.05 was considered as the cut-off value for significance. Table 1 shows socio-demographic and clinical characteristics of patients studied. During the three-year period under review 263 MCTs were done on symptomatic patients. No patient showed significant response to the diluent and no patient was unable to complete the test. As can be seen from Table 1 , there were no significant differences between the positive and negative groups.. According to our laboratory categorization of bronchial responsiveness (Table 3) , 79 patients (30%) out of 263 patients were positive for bronchial hyperresponsiveness, 20 of the positive patients (25.3%) had severe BHR, 18 patients (22.8%) had moderate BHR, and 41 patients (51.9%) had mild BHR. In Patients with severe BHR, 18 patients (90%) were presented with Chronic Cough and 3 patients (15%) presented with Shortness of Breath. In Patients with moderate BHR, 13 patients (72.2%) with Chronic Cough and 6 patients (33.3%) presented with Shortness of Breath. In Patents with mild BHR, 33 patients (80.5%) presented with Chronic Cough, while 14 patients (34.1%) presented with Shortness of Breath (Table 4) . Patients with severe and moderate BHR (38/79 patients) were treated as bronchial asthma. The mean of drop in FEV t from the baseline was 25.8% (Table 5) .
Results:

Discussion:
Bronchial hyper-responsiveness (BHR) is defined as an excessive response to an aerosolized provocation that elicits little or no response in a normal person. This feature appears to distinguish most patients with asthma, and underlies the rationale for bronchoprovocation testing. However BHR is also seen in many diseases other than asthma including chronic obstructive pulmonary disease (COPD), congestive heart failure, bronchitis, and allergic rhinitis, which give false positive MCT for asthma (5) . Bronchial challenge can be performed with Methacholine, Histamine, or others. Methacholine (a derivative of acetylcholine) is used more frequently than Histamine because the latter frequently induces flushing and headaches (8) .
MCT is usually considered when asthma is often a serious possibility and traditional spirometry performed before and after bronchodilators have not established or eliminated the diagnosis, or when patients present with symptoms which could result from asthma, but are ill-defined or nonspecific (e.g., cough, shortness of breath) (2) . Asthma is one of the important causes of unexplained chronic cough. In one study on 102 patients, asthma was the cause of chronic cough in 24% of cases (2) . In our review, 208 patients (79%) out of 263 patients had chronic cough (24 patients had dyspnea too), only 31 patients (14.9%) had moderate or severs BHR, and they were considered asthmatics (Table 4 ). Perpina et al. concluded from his study that the optimal diagnostic value of MCT (the highest combination of positive and negative power) occurs when the pretest probability of asthma (presence of typical symptoms and triggers of asthma) is 30-70% (11) . In our review of 263 patients who have some symptoms of asthma (cough, subjective dyspnea, or both), 38 patients (14.5%) had moderate and severe BHR, and were diagnosed and treated as asthma, and this low figure can be explained by the fact that no patient in our review had past history of asthma. The other point is that we only considered the fall in FEVj (PC 20-FEV1) as the primary outcome measure for MCT, and 35% fall in sGaw as the primary outcome in patients who cannot perform acceptable spirometry but we did not consider the fall in other parameters like FVC or FEF 25-75. Goldstein et al. reported in his study that the sensitivity of MCT determined by FEVj alone was only 60 percent, but increased to 97 percent after changes in FEF 25-75, FVC, sGaw, and thoracic gas volume were added to the analysis (9) , however in general, the sensitivity of a positive methacholine challenge test for the diagnosis of asthma is 85% (10) .
The negative predictive value of MCT is greater than the positive predictive value. In our review MCT was negative in 184/263 patients (70%) of cases, i.e. asthma was excluded confidently in 70% of cases.
